1. Co-Diagnostics Eyes Q3 '26 India TB Test Launch as CoSara SPAC Deal Looms
Co-Diagnostics is navigating a critical dual-track strategy, aiming to commercialize its tuberculosis test in India by the third quarter of 2026 while simultaneously exploring a potential SPAC transaction for its subsidiary, CoSara. This move signals a pivotal moment for the molecular diagnostics firm as it seeks to un...